News

Neuroprotective Mechanisms of Anavex 2-73 Revealed in Preclinical Study

New preclinical data have shown for the first time the underlying mechanisms mediating the therapeutic activity of Anavex 2-73, an investigational therapy being evaluated for the treatment of neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). Anavex Life Sciences’ investigational activator of the sigma-1 receptor…